Cargando…

Expression patterns of the immune checkpoint ligand CD276 in urothelial carcinoma

BACKGROUND: CD276 is an immune checkpoint molecule. Elevated CD276 expression by urothelial carcinoma is associated with poor prognosis, but little is known about its expression across different tumor stages. We therefore investigated CD276 expression in bladder cancer (BC) cells and in tissue sampl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Aicher, Wilhelm K., Korn, M., Reitnauer, L., Maurer, F. B., Hennenlotter, J., Black, P. C., Todenhofer, T., Bedke, J., Stenzl, A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8042686/ https://www.ncbi.nlm.nih.gov/pubmed/33845814 http://dx.doi.org/10.1186/s12894-021-00829-0

Ejemplares similares

Elevated Expression of the Immune Checkpoint Ligand CD276 (B7-H3) in Urothelial Carcinoma Cell Lines Correlates Negatively with the Cell Proliferation
por: Harland, Niklas, et al.
Publicado: (2022)

Regulation of Immune Checkpoint Antigen CD276 (B7-H3) on Human Placenta-Derived Mesenchymal Stromal Cells in GMP-Compliant Cell Culture Media
por: Amend, Bastian, et al.
Publicado: (2023)

Performance of Urinary Markers for Detection of Upper Tract Urothelial Carcinoma: Is Upper Tract Urine More Accurate than Urine from the Bladder?
por: Bier, Simone, et al.
Publicado: (2018)

CD24: A Marker for an Extended Expansion Potential of Urothelial Cancer Cell Organoids In Vitro?
por: Geng, Ruizhi, et al.
Publicado: (2022)

Systemic Alterations of Wnt Inhibitors in Patients with Prostate Cancer and Bone Metastases
por: Aufderklamm, Stefan, et al.
Publicado: (2018)

Differential Expression and Clinical Relevance of C-X-C Motif Chemokine Receptor 4 (CXCR4) in Renal Cell Carcinomas, Benign Renal Tumors, and Metastases
por: Maas, Moritz, et al.
Publicado: (2023)

Checkpoint modulation - A new way to direct the immune system against renal cell carcinoma
por: Bedke, Jens, et al.
Publicado: (2015)

Circulating tumor cells and their role in prostate cancer
por: Maas, Moritz, et al.
Publicado: (2019)

Effects of Scaffolds on Urine- and Urothelial Carcinoma Tissue-Derived Organoids from Bladder Cancer Patients
por: Walz, Simon, et al.
Publicado: (2023)

Urinary Tract Tumor Organoids Reveal Eminent Differences in Drug Sensitivities When Compared to 2-Dimensional Culture Systems
por: Wei, Yi, et al.
Publicado: (2022)

Current concepts and trends in the treatment of bone metastases in patients with advanced prostate cancer
por: Hegemann, Miriam, et al.
Publicado: (2019)

Digital expression profile of immune checkpoint genes in medulloblastomas identifies CD24 and CD276 as putative immunotherapy targets
por: Marques, Rui Ferreira, et al.
Publicado: (2023)

Prospective evaluation of fluorescence-guided cystoscopy to detect bladder cancer in a high-risk population: results from the UroScreen-Study
por: Horstmann, Marcus, et al.
Publicado: (2014)

Assessment of a new point-of-care system for detection of prostate specific antigen
por: Rausch, Steffen, et al.
Publicado: (2016)

New frontiers in immune checkpoint B7-H3 (CD276) research and drug development
por: Getu, Ayechew Adera, et al.
Publicado: (2023)

Immune checkpoint inhibitors for urothelial carcinoma
por: Kim, Hyung Suk, et al.
Publicado: (2018)

Economic aspects of bladder cancer: what are the benefits and costs?
por: Sievert, K. D., et al.
Publicado: (2009)

The immune checkpoint B7-H3 (CD276) regulates adipocyte progenitor metabolism and obesity development
por: Picarda, Elodie, et al.
Publicado: (2022)

Point-of-Care Tests for Bladder Cancer: The Influencing Role of Hematuria
por: Hennenlotter, Joerg, et al.
Publicado: (2011)

MCT4 surpasses the prognostic relevance of the ancillary protein CD147 in clear cell renal cell carcinoma
por: Fisel, Pascale, et al.
Publicado: (2015)

Immune Checkpoint Inhibitors in the Management of Urothelial Carcinoma
por: Patel, Aakash, et al.
Publicado: (2021)

Utility of pT3 substaging in lymph node-negative urothelial carcinoma of the bladder: do pathologic parameters add to prognostic sub-stratification?
por: Maas, Moritz, et al.
Publicado: (2021)

Severe paraneoplastic hypereosinophilia in metastatic renal cell carcinoma
por: Todenhöfer, Tilman, et al.
Publicado: (2012)

The MDM2 ligand Nutlin-3 differentially alters expression of the immune blockade receptors PD-L1 and CD276
por: Li, Ruidong, et al.
Publicado: (2020)

The Role of CD276 in Cancers
por: Liu, Shengzhuo, et al.
Publicado: (2021)

The Evolution of Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma
por: Houssiau, Hélène, et al.
Publicado: (2022)

Intratumoral Heterogeneity Determines the Expression of mTOR-pathway Proteins in Prostate Cancer
por: Russo, Giorgio Ivan, et al.
Publicado: (2019)

Role of Multiparametric Magnetic Resonance Imaging in Predicting Pathologic Outcomes in Prostate Cancer
por: Harland, Niklas, et al.
Publicado: (2021)

Biomarkers of the Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma
por: Chen, Siteng, et al.
Publicado: (2020)

Combination Biomarker of Immune Checkpoints Predict Prognosis of Urothelial Carcinoma
por: Tsai, Chung-Ying, et al.
Publicado: (2021)

Predictive biomarkers for immune checkpoint inhibitor response in urothelial cancer
por: Parent, Pauline, et al.
Publicado: (2023)

Role of the Systemic Immune-Inflammation Index in Patients with Metastatic Renal Cell Carcinoma Treated with First-Line Ipilimumab plus Nivolumab
por: Stühler, Viktoria, et al.
Publicado: (2022)

Development of secondary urothelial carcinoma following complete response to immune checkpoint inhibitors
por: Lavoie, Jean-Michel, et al.
Publicado: (2021)

Large Animal Models for Investigating Cell Therapies of Stress Urinary Incontinence
por: Amend, Bastian, et al.
Publicado: (2021)

OX40 (CD134) and OX40 ligand, important immune checkpoints in cancer
por: Deng, Juan, et al.
Publicado: (2019)

Machine Learning for Prediction of Survival Outcomes with Immune-Checkpoint Inhibitors in Urothelial Cancer
por: Abuhelwa, Ahmad Y., et al.
Publicado: (2021)

Immune checkpoint inhibitors in urothelial cancer: recent updates and future outlook
por: Gopalakrishnan, Dharmesh, et al.
Publicado: (2018)

Immune checkpoint inhibitors as a real hope in advanced urothelial carcinoma
por: Seront, Emmanuel, et al.
Publicado: (2018)

Adverse Effects and Toxicity of Immune Checkpoint Inhibitors For Patients With Urothelial Carcinoma
por: Wang, Di, et al.
Publicado: (2021)

Cost-Effectiveness of Immune Checkpoint Inhibitors in Urothelial Carcinoma—A Review
por: Walia, Arman S., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_4tvg4o6p6au77tv7g4hk928ie4